Drug Profile
Docetaxel - Vivesto
Alternative Names: Docecal; Docetaxel micellar - Vivesto; Docetaxel-XR-17; XR-17-docetaxelLatest Information Update: 08 Aug 2023
Price :
$50
*
At a glance
- Originator Oasmia Pharmaceutical
- Developer Swiss Group for Clinical Cancer Research; Vivesto
- Class Antineoplastics; Radiopharmaceutical diagnostics; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Prostate cancer
- No development reported Breast cancer
Most Recent Events
- 04 Aug 2023 Vivesto terminates enrolment early in a phase Ib trial for Prostate cancer (First-line therapy, Metastatic disease, Hormone refractory) in Switzerland (IV) (NCT04629781)
- 11 Oct 2021 No development reported - Phase-III for Breast cancer (In the elderly, Second-line therapy or greater, In adults) in Latvia (IV)
- 01 Jun 2021 Phase-I clinical trials in Prostate cancer (First-line therapy, Metastatic disease, Hormone refractory) in Switzerland (IV)